Strategic Initiatives and Refined Business Model Produced Financial and Operating EfficienciesEstablished Long-Term License and Supply Agreement ...

As one long-running feud over the controversial generic drug carveout known as “skinny” labeling comes to a close, the United States’ top lawyer is urging the Supreme Court to reverse a recent ...

Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today issued a call to action for American Heart Month emphasizing a ...

Amarin's heart drug Vascepa is casting its net with a first-ever TV ad campaign. Although the triglyceride-lowering drug has been on the market for five years, Amarin is anticipating cardiovascular ...

Amarin Corp PLC (AMRN) reports a challenging quarter with decreased revenues but showcases resilience through strategic alliances and significant cost management.

Amarin (AMRN) stock drops 9% after the Irish biotech missed Street forecasts with its Q4 2025 revenue. Read more here.

AMRN swings to Q4 profit and beats estimates, but revenues decline 21% as Vascepa sales slide and shares fall 9% on the mixed results.

Plus, how gene-editing company CRISPR Therapeutics just took a big step forward. To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. To get started investing, ...

An appeal hearing for Vascepa's patent case isn't sitting well with investors. Amarin's shares bounced off their lows of the day, but then closed today down almost 31%. Last March, Vascepa's patents ...